Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Radiopharm Theranostics Limited Sponsored ADR, retaining the price target of $30.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Walsh has given his Buy rating due to a combination of factors surrounding Radiopharm Theranostics Limited’s promising clinical developments. The interim data from their Phase IIb trial of F-18-RAD101 in brain metastases showed a high degree of positive correlation between MRI and PET imaging, indicating the potential clinical utility of RAD101. This utility is particularly significant in distinguishing between necrosis and living tumor tissue in patients post stereotactic radiosurgery, which could enhance diagnostic accuracy and treatment decisions.
Furthermore, the anticipated topline readout for the full Phase IIb trial and the potential start of a Phase III trial suggest a promising trajectory for RAD101, pending favorable outcomes and FDA feedback. Additionally, Radiopharm’s broader portfolio of imaging and therapeutic radiopharmaceutical agents positions the company for medium- to long-term growth, with opportunities for non-dilutive capital through partnerships. The potential of clinical assets like RAD101 and RAD204 is considered underappreciated, and they could drive significant value as more favorable clinical data emerges.
In another report released today, B. Riley Securities also maintained a Buy rating on the stock with a $16.00 price target.